busulfan has been researched along with Juvenile Chronic Myelogenous Leukemia in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Most patients with juvenile myelomonocytic leukemia (JMML) are curable only with allogeneic hematopoietic cell transplantation (HCT)." | 2.87 | Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. ( Cairo, MS; Cooper, T; Dang, H; Dvorak, CC; Gao, Y; Grupp, SA; Hirsch, B; Kahwash, S; Loh, ML; Mazor, T; Mehta, PA; Olshen, AB; Parker, JS; Patel, N; Pei, Q; Raimondi, S; Satwani, P; Skeens, M; Stieglitz, E; Wall, D, 2018) |
| "Human Severe Combined Immunodeficiency (SCID) is a prenatal disorder of T lymphocyte development that depends on the expression of numerous genes." | 1.39 | Tooth developmental anomalies in severe combined immunodeficiency disease and juvenile myelomonocytic leukemia: common clinical features and treatment outcomes. ( Angiero, F; Benedicenti, S; Cossellu, G; Farronato, G; Olivi, G; Seramondi, R, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Li, G | 1 |
| Sun, Z | 1 |
| Geng, L | 1 |
| Wan, X | 1 |
| Zhu, X | 1 |
| Tang, B | 1 |
| Tong, J | 1 |
| Yao, W | 1 |
| Song, K | 1 |
| Qiang, P | 1 |
| Zhang, L | 1 |
| Zhang, X | 1 |
| Zhang, S | 1 |
| Liu, H | 1 |
| Yi, ES | 1 |
| Kim, SK | 1 |
| Ju, HY | 1 |
| Lee, JW | 1 |
| Cho, B | 1 |
| Kim, BK | 1 |
| Kang, HJ | 1 |
| Baek, HJ | 1 |
| Kook, H | 1 |
| Yang, EJ | 1 |
| Lim, YT | 1 |
| Ahn, WK | 1 |
| Hahn, SM | 1 |
| Park, SK | 1 |
| Yoo, ES | 1 |
| Yoo, KH | 1 |
| Yoshida, N | 2 |
| Sakaguchi, H | 1 |
| Yabe, M | 3 |
| Hasegawa, D | 2 |
| Hama, A | 1 |
| Kato, M | 1 |
| Noguchi, M | 1 |
| Terui, K | 1 |
| Takahashi, Y | 1 |
| Cho, Y | 1 |
| Sato, M | 1 |
| Koh, K | 1 |
| Kakuda, H | 2 |
| Shimada, H | 1 |
| Hashii, Y | 1 |
| Sato, A | 1 |
| Kato, K | 1 |
| Atsuta, Y | 1 |
| Watanabe, K | 2 |
| Dvorak, CC | 1 |
| Satwani, P | 1 |
| Stieglitz, E | 1 |
| Cairo, MS | 1 |
| Dang, H | 1 |
| Pei, Q | 1 |
| Gao, Y | 1 |
| Wall, D | 1 |
| Mazor, T | 1 |
| Olshen, AB | 1 |
| Parker, JS | 1 |
| Kahwash, S | 1 |
| Hirsch, B | 1 |
| Raimondi, S | 1 |
| Patel, N | 1 |
| Skeens, M | 1 |
| Cooper, T | 1 |
| Mehta, PA | 1 |
| Grupp, SA | 1 |
| Loh, ML | 1 |
| Cossellu, G | 1 |
| Seramondi, R | 1 |
| Benedicenti, S | 1 |
| Farronato, G | 1 |
| Olivi, G | 1 |
| Angiero, F | 1 |
| Guilcher, GM | 1 |
| Moorjani, R | 1 |
| Truong, TH | 1 |
| Lewis, VA | 1 |
| Ohtsuka, Y | 2 |
| Inagaki, J | 1 |
| Sakashita, K | 1 |
| Yabe, H | 2 |
| Kurosawa, H | 2 |
| Kudo, K | 1 |
| Manabe, A | 2 |
| Sako, M | 1 |
| Osugi, Y | 1 |
| Nara, T | 1 |
| Tokuyama, M | 1 |
| Adachi, S | 1 |
| Kobayashi, C | 1 |
| Yanagimachi, M | 1 |
| Nakazawa, Y | 1 |
| Ogawa, C | 1 |
| Kojima, S | 1 |
| Nakahata, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Modified Post-Transplant Cyclophosphamide Combined With DCAG as a Bridge Followed by Busulfan, Fludarabine and Melphalan Based Conditioning Regimen for Children With Juvenile Myelomonocytic Leukemia[NCT03687463] | 6 participants (Actual) | Observational [Patient Registry] | 2015-04-10 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for busulfan and Juvenile Chronic Myelogenous Leukemia
| Article | Year |
|---|---|
Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study.
Topics: Busulfan; Child; Child, Preschool; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease | 2018 |
7 other studies available for busulfan and Juvenile Chronic Myelogenous Leukemia
| Article | Year |
|---|---|
Clinical outcome of cord blood transplantation for nine children with juvenile myelomonocytic leukemia receiving fludarabine-busulfan-cyclophosphamide-based conditioning.
Topics: Antineoplastic Agents; Busulfan; Child; Child, Preschool; China; Cord Blood Stem Cell Transplantatio | 2022 |
Allogeneic hematopoietic cell transplantation in patients with juvenile myelomonocytic leukemia in Korea: a report of the Korean Pediatric Hematology-Oncology Group.
Topics: Busulfan; Child; Graft vs Host Disease; Hematology; Hematopoietic Stem Cell Transplantation; Humans; | 2023 |
Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell Transplantation.
Topics: Busulfan; Child; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Japan; Leuk | 2020 |
Tooth developmental anomalies in severe combined immunodeficiency disease and juvenile myelomonocytic leukemia: common clinical features and treatment outcomes.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Child; Cycloph | 2013 |
Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation.
Topics: Antilymphocyte Serum; Busulfan; Child, Preschool; Combined Modality Therapy; Hematopoietic Stem Cell | 2015 |
Transplantation for juvenile myelomonocytic leukemia: a retrospective study of 30 children treated with a regimen of busulfan, fludarabine, and melphalan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Graft vs | 2015 |
A conditioning regimen of busulfan, fludarabine, and melphalan for allogeneic stem cell transplantation in children with juvenile myelomonocytic leukemia.
Topics: Administration, Oral; Busulfan; Child; Child, Preschool; Female; History, Ancient; Humans; Immunosup | 2008 |